Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2019

View Archived Issues

Staph toxin does double duty

Large-scale identification of regulatory targets

Basilea reports interim data from phase II study of derazantinib in iCCA with FGFR2 gene fusions

Lysogene initiates phase II/III study of its AAV/rh.10-SGSH gene therapy

Cellular Biomedicine begins enrollment in phase I study of C-CAR088 for multiple myeloma in China

Discovery of a novel series of IDH1 inhibitors with promising preclinical activity

Identification of novel SSTR5-selective antagonists with improved stability and pharmacokinetics

Interaction of CSF with graphene causes changes in its vibrational energies that distinguish ALS

Competitive single molecule arrays for highly sensitive detection of small molecules

Development of the first class of YEATS domain inhibitors by targeting the pi-pi-pi stacking

New nanoformulations for oral delivery of antiparasitic triclabendazole with better bioavailability

EMBL patents pirin-targeting compounds

Synthetic sodium channel blockers demonstrate anticancer effects in prostate cancer cells

Genentech and Roche present new IRAK-4 inhibitors

NIAID analysis shows phase IIb study of FLU-v met primary endpoint

NIAID studies rCSP malaria vaccine with and without adjuvant in healthy subjects

New phase I trial studies GPC3-CAR-T cells in pediatric GPC3-positive solid tumors

Relugolix receives first approval in Japan for the treatment of uterine fibroids

Osteoporosis genetic atlas identifies potential new drug targets

Combination beta-lactamase inhibitor and antibiotic product Zarvaxa approved in Japan

Opdivo demonstrates significant extension in OS in phase III ATTRACTION-3 study

Enterin initiates phase IIb KARMET study of ENT-01

Sirion Biotech collaborates with Denali Therapeutics to develop gene therapies for CNS diseases

Vizimpro approved in Japan for the treatment of EGFR-mutated NSCLC